Oxycodone Hydrochloride, USP.4.8355 mg*Īspirin, USP.325 mg DESCRIPTIONĮach PERCODAN (aspirin and oxycodone hydrochloride) Tablet contains: You may report side effects to FDA at 1-80. For more information, ask your doctor or pharmacist.Ĭall your doctor for medical advice about side effects. These are not all the possible side effects of Percodan. Tell the doctor if you have any side effect that bothers you or that does not go away. The most common side effects of Percodan include: Get medical help right away, if you have any of the symptoms listed above. swelling of your face, lips, tongue, or throat,.Percodan may cause serious side effects including: What are the possible side effects of Percodan? It is not known if Percodan is safe and effective in children. Percodan belongs to a class of drugs called Analgesics, NSAID/ Opioid Combos. Percodan may be used alone or with other medications. (Funded by Bristol-Myers Squibb and Pfizer number, NCT00496769.).Percodan is a prescription medicine used to treat the symptoms of Moderate to Moderately Severe Pain. In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing the risk of major bleeding or intracranial hemorrhage. The treatment effects were consistent among important subgroups. The risk of a first hospitalization for cardiovascular causes was reduced with apixaban as compared with aspirin (12.6% per year vs. There were 44 cases of major bleeding (1.4% per year) in the apixaban group and 39 (1.2% per year) in the aspirin group (hazard ratio with apixaban, 1.13 95% CI, 0.74 to 1.75 P=0.57) there were 11 cases of intracranial bleeding with apixaban and 13 with aspirin. The rates of death were 3.5% per year in the apixaban group and 4.4% per year in the aspirin group (hazard ratio, 0.79 95% CI, 0.62 to 1.02 P=0.07). There were 51 primary outcome events (1.6% per year) among patients assigned to apixaban and 113 (3.7% per year) among those assigned to aspirin (hazard ratio with apixaban, 0.45 95% confidence interval, 0.32 to 0.62 P<0.001). The data and safety monitoring board recommended early termination of the study because of a clear benefit in favor of apixaban. The primary outcome was the occurrence of stroke or systemic embolism.īefore enrollment, 40% of the patients had used a vitamin K antagonist. In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation.
0 kommentar(er)
